Home/ Stocks/ RIGL

Rigel Pharmaceuticals Inc. (New)

RIGL XNAS

$26.04 -0.24 (-0.91%) ▼ 15-min delayed

Open

$26.24

High

$26.96

Low

$26.00

Volume

299.4K

Market Cap

$481.79M

About Rigel Pharmaceuticals Inc. (New)

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 174 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$58.82M	$8.65M	$0.47
FY 2025	$294.28M	$367.02M	$20.40
Q3 2025	$69.46M	$27.90M	$1.55
Q2 2025	$101.69M	$59.61M	$3.33

Earnings & Analyst Ratings

Next Earnings: Mon, Aug 3, 2026

Calendar →

Related Market News

No specific coverage for RIGL yet. Check out our latest market news or earnings calendar.

Get RIGL Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Rigel Pharmaceuticals Inc. (New).

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.